methyl 2-amino-3-oxo-3-phenylpropanoate hydrochloride

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl 2-amino-3-oxo-3-phenylpropanoate hydrochloride
• 英文别名: methyl benzoylglycinate hydrochloride；(1-Methoxy-1,3-dioxo-3-phenylpropan-2-yl)azanium;chloride；(1-methoxy-1,3-dioxo-3-phenylpropan-2-yl)azanium;chloride
• 化学式: C₁₀H₁₁NO₃*ClH
• 分子量: 229.663
• InChiKey: RKYMFPGHEJNRRP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.79
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  69.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 2-amino-3-oxo-3-phenylpropanoate hydrochloride 在 C₃₁H₃₇ClN₂O₂RuS 、 甲酸铵 作用下， 以 乙腈 为溶剂， 反应 4.0h， 生成 (2RS,3RS)-2-amino-3-hydroxy-3-phenyl-propionic acid methyl ester; hydrochloride
  参考文献：
  名称：

  通过动态动力学拆分对α-氨基β-酮酯盐酸盐进行不对称转移加氢†

  摘要：

  描述了Ru催化α-氨基β-酮酸酯盐酸盐的不对称转移加氢反应的进展。反应通过动态动力学拆分进行，得到具有良好非对映异构体比率和高对映选择性的抗β-羟基α-氨基酯。

  DOI：

  10.1039/c5ra10385a
• 作为产物：
  描述：

  methyl 2-((tert-butoxycarbonyl)amino)-3-oxo-3-phenylpropanoate 在 盐酸 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 生成 methyl 2-amino-3-oxo-3-phenylpropanoate hydrochloride
  参考文献：
  名称：

  乳液中不对称转移加氢合成对-β-羟基-α-酰胺基酯的对映选择性

  摘要：

  本文中，我们介绍了两种通过α-氨基-β-酮酸酯的动态动力学拆分进行不对称转移氢化的方法。这些步骤可产生相应的抗-β-羟基-α-酰胺基酯，收率高，具有非对映和对映选择性。首先，研究了使用甲酸三乙铵共沸物还原α-氨基-β-酮酸酯的范围。然后，研究了使用甲酸钠的乳液技术，该技术可扩大底物范围，缩短反应时间并降低催化剂负载量。此外，这些反应操作简单，可以在空气中进行。

  DOI：

  10.1002/chem.201103739

文献信息

• [EN] MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS<br/>[FR] MERCAPTOIMIDAZOLES SERVANT D'ANTAGONISTES DU RÉCEPTEUR CCR2
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2006015986A1

  公开（公告）日：2006-02-16

  The present invention relates to a compound of formula (I), a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein R1 represents hydrogen, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxyC1-6alkyl, di(C1-6alkyl)amino C1-6alkyl, aryl or heteroaryl; each R2 independently represents halo, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, polyhalo C1-6alkyl, polyhalo C1-6alkyloxy, cyano, aminocarbonyl, amino, mono-or di(C1-4alkyl)amino, nitro, aryl or aryloxy; R3 represents cyano, C(=O)-O-R5, C(=O)-ΝR6aR6b or C(=O)-R7; or a cyclic ring system; R4 represents hydrogen or C1-6alkyl; n is 1, 2, 3, 4 or 5; R10 represents hydrogen, C1-6alkyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, arylcarbonyl, heteroarylcarbonyl, -C(=0)-NH-R5, -C(=S)-NH-R5 or -S(=O)2-R5. The invention also relates to processes for preparing the compounds of formula (I), their use as CCR2 antagonists and pharmaceutical compositions comprising them.

  本发明涉及一种式(I)的化合物，一种N-氧化物，一种药学上可接受的加合盐，一种季铵盐和其立体化学异构体形式，其中R1代表氢，C1-6烷基，C3-7环烷基，C1-6烷氧基C1-6烷基，二(C1-6烷基)氨基C1-6烷基，芳基或杂环芳基；每个R2独立地代表卤素，C1-6烷基，C1-6烷氧基，C1-6烷硫基，多卤素C1-6烷基，多卤素C1-6烷氧基，氰基，氨基甲酰基，氨基，单或双(C1-4烷基)氨基，硝基，芳基或芳氧基；R3代表氰基，C(=O)-O-R5，C(=O)-ΝR6aR6b或C(=O)-R7；或者是一个环状环系统；R4代表氢或C1-6烷基；n为1、2、3、4或5；R10代表氢，C1-6烷基，C1-6烷基羰基，C1-6烷氧羰基，芳基羰基，杂环芳基羰基，-C(=0)-NH-R5，-C(=S)-NH-R5或-S(=O)2-R5。该发明还涉及制备式(I)化合物的方法，它们作为CCR2拮抗剂的用途以及包含它们的药物组合物。
• [EN] OXAZOLE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS OXAZOLE ANTAGONISTES DES RÉCEPTEURS D'OREXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2015018029A1

  公开（公告）日：2015-02-12

  The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及氧唑化合物，其为促进睡眠的受体拮抗剂。本发明还涉及所述氧唑化合物在潜在治疗或预防涉及促进睡眠的神经和精神障碍和疾病中的用途。本发明还涉及包含这些化合物的药物组合物。本发明还涉及这些药物组合物在预防或治疗涉及促进睡眠的疾病中的用途。
• [EN] OXAZOLE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE RÉCEPTEUR D'OREXINE À BASE D'OXAZOLE
  申请人：MERCK SHARP & DOHME

  公开号：WO2015020930A1

  公开（公告）日：2015-02-12

  The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及氧唑化合物，其为促进素受体的拮抗剂。本发明还涉及所述氧唑化合物在潜在的治疗或预防涉及促进素受体的神经和精神障碍和疾病中的用途。本发明还涉及包含这些化合物的药物组合物。本发明还涉及这些药物组合物在预防或治疗涉及促进素受体的疾病中的用途。
• Rhodium-catalyzed asymmetric hydrogenation through dynamic kinetic resolution: asymmetric synthesis of anti-β-hydroxy-α-amino acid esters
  作者：Kazuishi Makino、Takefumi Fujii、Yasumasa Hamada

  DOI：10.1016/j.tetasy.2006.01.040

  日期：2006.2

  Rhodium-catalyzed asymmetric hydrogenation of α-amino-β-keto ester hydrochlorides through dynamic kinetic resolution is described. The hydrogenation proceeds with the catalyst derived from a Rh complex and a chiral ferrocenylphosphine under hydrogen in the presence of sodium acetate in acetic acid to afford anti-β-hydroxy-α-amino acid esters with 58–83% ee in a diastereomeric ratio of 92:8–97:3.

  描述了铑通过动态动力学拆分催化α-氨基-β-酮酯盐酸盐的不对称加氢反应。在乙酸钠的存在下，在乙酸中，在氢气下，氢化衍生自Rh络合物和手性二茂铁基膦的催化剂进行氢化，制得抗-β-羟基-α-氨基酸酯，其对映体比率为58-83％ee。 92：8–97：3。
• An efficient synthesis and acylation of α-amino-β-keto-esters: Versatile intermediates in the synthesis of peptide mimetics.
  作者：Jasbir Singh、Thomas D. Gordon、William G. Earley、Barry A. Morgan

  DOI：10.1016/s0040-4039(00)60549-x

  日期：1993.1

  A flexible and high yield synthesis of α-amino-β-keto esters has been developed via acylation of the ketimine derivatives of α-amino esters. These α-amino-β-keto-esters were acylated with chiral amino acid derivatives in 36–95% yields.

  通过酰化α-氨基酯的酮亚胺衍生物，已经开发了一种灵活且高产率的α-氨基-β-酮酯的合成方法。这些α-氨基-β-酮基酯被手性氨基酸衍生物酰化，收率为36-95％。